Tags

Type your tag names separated by a space and hit enter

MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice.
Neuropediatrics. 2018 02; 49(1):3-11.N

Abstract

Myelin oligodendrocyte glycoprotein (MOG) antibodies (abs) are present in one third of all children with an acute demyelinating syndrome (ADS). MOG-abs can be found in acute disseminated encephalomyelitis (ADEM), transverse myelitis, isolated optic neuritis (ON), or recurrent demyelinating diseases, such as multiphasic neuromyelitis optica spectrum disorders (NMOSD) without aquaporin-4 (AQP4) abs or multiphasic ADEM (MDEM), but rarely in children who subsequently develop multiple sclerosis (MS). The presence of MOG-abs is age dependent with the highest seropositivity rates found in young children and an episode of ADEM, whereas older children with MOG-abs present with ON, myelitis, or brainstem symptoms. MOG-abs, initially thought to be associated with a benign disease course, are found in a substantial proportion of children with relapsing episodes associated with high and persisting MOG-ab titers. This review describes, in particular, the increasing spectrum of phenotypes associated with MOG-abs with a focus on clinical characteristics, radiological features, and therapeutic aspects.

Authors+Show Affiliations

Department of Paediatrics, Olga Hospital, Stuttgart, Germany.Division of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.Division of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.Department of Pediatric Neurology, Vestische Kinder- und Jugendklinik Datteln, Witten/Herdecke University, Datteln, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28859212

Citation

Hennes, Eva-Maria, et al. "MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice." Neuropediatrics, vol. 49, no. 1, 2018, pp. 3-11.
Hennes EM, Baumann M, Lechner C, et al. MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. Neuropediatrics. 2018;49(1):3-11.
Hennes, E. M., Baumann, M., Lechner, C., & Rostásy, K. (2018). MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. Neuropediatrics, 49(1), 3-11. https://doi.org/10.1055/s-0037-1604404
Hennes EM, et al. MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. Neuropediatrics. 2018;49(1):3-11. PubMed PMID: 28859212.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice. AU - Hennes,Eva-Maria, AU - Baumann,Matthias, AU - Lechner,Christian, AU - Rostásy,Kevin, Y1 - 2017/08/31/ PY - 2017/9/1/pubmed PY - 2018/8/15/medline PY - 2017/9/1/entrez SP - 3 EP - 11 JF - Neuropediatrics JO - Neuropediatrics VL - 49 IS - 1 N2 - Myelin oligodendrocyte glycoprotein (MOG) antibodies (abs) are present in one third of all children with an acute demyelinating syndrome (ADS). MOG-abs can be found in acute disseminated encephalomyelitis (ADEM), transverse myelitis, isolated optic neuritis (ON), or recurrent demyelinating diseases, such as multiphasic neuromyelitis optica spectrum disorders (NMOSD) without aquaporin-4 (AQP4) abs or multiphasic ADEM (MDEM), but rarely in children who subsequently develop multiple sclerosis (MS). The presence of MOG-abs is age dependent with the highest seropositivity rates found in young children and an episode of ADEM, whereas older children with MOG-abs present with ON, myelitis, or brainstem symptoms. MOG-abs, initially thought to be associated with a benign disease course, are found in a substantial proportion of children with relapsing episodes associated with high and persisting MOG-ab titers. This review describes, in particular, the increasing spectrum of phenotypes associated with MOG-abs with a focus on clinical characteristics, radiological features, and therapeutic aspects. SN - 1439-1899 UR - https://www.unboundmedicine.com/medline/citation/28859212/MOG_Spectrum_Disorders_and_Role_of_MOG_Antibodies_in_Clinical_Practice_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0037-1604404 DB - PRIME DP - Unbound Medicine ER -